FOR OVERWEIGHT AND OBESITY:
WEIGHT MANAGEMENT
is becoming an increasingly important topic in general practice.
MARKET OBSERVATIONS SHOW:
Since 2023, prescriptions of GLP‑1 therapies for the indication of obesity have increased exponentially, most recently showing a rise of 130%.³
High media attention is driving active patient demand for GLP‑1 agonists.³
Weight loss is increasingly becoming a reason for GP consultations.3,4
This makes your medical counselling the most important pillar of weight management.
Weight loss with injections?
Effective – but not fully thought through1,2
Discontinuation of weight‑loss injections is often only a matter of time. What can happen afterwards is now well documented.
Results from a recent systematic review based on 9,341 patients,
with a mean GLP‑1 treatment duration of 39 weeks, show the following after therapy discontinuation:¹
9.9 KG IN THE FIRST YEAR
9.9 KG
Mean monthly weight regain amounted to 0.8 kg after discontinuation of the more effective GLP‑1 agonists.
Mean monthly weight regain amounted to 0.8 kg after discontinuation of the more effective GLP‑1 agonists.
ONLY 1.4 YEARS
1.4 years
A return of all cardiometabolic parameters to baseline levels was predicted within 1.4 years.
A return of all cardiometabolic parameters to baseline levels was predicted within 1.4 years.
As a result, patients frequently ask:
How long can I afford GLP‑1 therapy?*
How can I prevent the yo‑yo effect after stopping injections?
What side effects should I expect?
What can I do if I am afraid of injections?
This makes your ongoing medical guidance and support all the more essential.
We support you with a therapy option that meaningfully complements GLP‑1 and can help optimise weight management.
* BMI > 30 kg/m² is more common in lower‑income population groups.⁵
formoline L112 EXTRA
Think beyond weight‑loss injections with us – to support your patients holistically in weight management.
Why formoline L112 EXTRA?
Post‑GLP‑1: helps counteract the yo‑yo effect
More cost‑effective for long‑term use
No injections required (oral administration)6
Pre‑GLP‑1: suitable as an entry therapy for patients with overweight who are undecided
High tolerability (purely physical mode of action, non‑systemic)6
Clinically relevant efficacy7
EXPERT STATEMENTS
on the current situation in general practice
“A change in behaviour and nutrition is always my first recommendation. If this does not lead to success and there is an indication for GLP‑1 therapy, I initiate treatment—provided patients can afford the costs and do not have a fear of injections. This is also where the greatest need lies: many patients require a more affordable alternative or follow‑up therapy that can be administered orally.”
Dr Moritz Sieber
“Many of my patients do not have the financial means to pay for long‑term GLP‑1 treatment—we are, after all, talking about a therapy duration of at least one year. This negatively affects adherence, sometimes to the point where dosing intervals are extended or injections are only partially used. These patients can benefit from a more affordable follow‑up therapy, especially if it is easy to use and well tolerated.”
Dr Moritz Sieber
“Around half of the patients I see are overweight or have obesity. Accordingly, there is a high number of patients who want to lose weight and actively ask about GLP‑1 therapy. This requires careful expectation management—regarding patient self‑discipline as well as costs, tolerability and the long‑term sustainability of these treatments. We must also consider the level of frustration in patients whose previous weight‑loss attempts have been unsuccessful, which can lead to depressive symptoms. Therefore, therapeutic options that delay the use of GLP‑1 or serve as an off‑ramping strategy can be highly valuable.”
Dr Hasso Krause
“Typically, my patients receive GLP‑1 therapy for up to two years. Once the target weight has been achieved, I gradually taper off treatment. Unfortunately, discontinuation of these medications often leads to a yo‑yo effect, meaning renewed weight gain, because the necessary lifestyle changes were not maintained. In addition to long‑term motivational support from the therapist, a well‑tolerated and more cost‑efficient follow‑up therapy would be helpful in maintaining the target weight.”
Dr Hasso Krause
FAQ
GLP‑1 in obesity
Results from a systematic review based on 9,341 patients, following an average treatment duration of 39 weeks with the more effective GLP-1 agonists, show an average monthly weight regain of 0.8kg1 after discontinuation of therapy.
In a systematic review based on 9,341 patients, a return of all cardiometabolic parameters to baseline values was predicted within 1.4 years.¹
formoline L112 EXTRA can be used both pre-GLP-1 as an entry therapy for overweight and post-GLP-1 to help counteract the yo-yo effect.
PRACTICE UPDATES
Stay Informed